## **CLAIMS**

- 1. A method for treating ischemic heart diseases, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1.
- 2. The method for treating ischemic heart diseases according to claim 1, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1, and in which a vascular endothelial growth factor is not administered.

5

10

15

20

25

30

35

- 3. The method according to claim 1 or 2, wherein angiopoietin-1 or the vector encoding angiopoietin-1 is a viral vector encoding angiopoietin-1.
  - 4. The method according to claim 3, wherein the viral vector is an adenoviral vector.
- 5. The method according to claim 3, wherein the viral vector is a minus-strand RNA viral vector.
- 6. The method according to claim 1 or 2, wherein angiopoietin-1 or the vector encoding angiopoietin-1 is a naked DNA.
- 7. The method according to any one of claims 1 to 6, wherein angiopoietin-1 or the vector encoding angiopoietin-1 is a vector that drives angiopoietin-1 expression using a CA promoter or a promoter having a transcriptional activity equivalent to or higher than that of said CA promoter.
- 8. The method according to any one of claims 1 to 7, wherein the administration of angiopoietin-1 or the vector encoding angiopoietin-1 is an injection into cardiac muscle.
- 9. A method for treating ischemic diseases, which comprises the step of administering a viral vector encoding angiopoietin-1.
- 10. The method for treating ischemic diseases according to claim 9, which comprises the step of administering a viral vector encoding angiopoietin-1, and wherein a vascular endothelial growth factor is not administered.
- 11. The method according to claim 9 or 10, wherein the viral vector is an adenoviral vector.
- 12. The method according to claim 9 or 10, wherein the viral vector is a minus-strand RNA viral vector.
- 13. The method according to any one of claims 9 to 12, wherein the vector administration is an injection into an ischemic site.
- 14. A genetically modified mesenchymal cell comprising a foreign gene encoding angiopoietin-1.
- 15. The mesenchymal cell according to claim 14, into which an adenoviral vector encoding angiopoietin-1 has been introduced.
  - 16. The mesenchymal cell according to claim 14, into which a minus-strand RNA viral

vector encoding angiopoietin-1 has been introduced.

5

- 17. A therapeutic composition for ischemia, which comprises the mesenchymal cell according to any one of claims 14 to 16 and a pharmaceutically acceptable carrier.
- 18. A method for producing a genetically modified mesenchymal cell, wherein the method comprises the step of contacting the mesenchymal cell with a minus-strand RNA viral vector carrying a gene.
  - 19. The method according to claim 18, wherein the gene encodes angiopoietin-1.